Last reviewed · How we verify
Ventavis (Iloprost, BAYQ6256)
Ventavis is a prostacyclin analogue that acts as a vasodilator to improve exercise capacity in patients with pulmonary arterial hypertension.
Ventavis is a prostacyclin analogue that acts as a vasodilator to improve exercise capacity in patients with pulmonary arterial hypertension. Used for Treatment of pulmonary arterial hypertension.
At a glance
| Generic name | Ventavis (Iloprost, BAYQ6256) |
|---|---|
| Sponsor | Bayer |
| Drug class | Prostacyclin analogue |
| Target | Prostacyclin receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Iloprost works by binding to and activating prostacyclin receptors, leading to relaxation of vascular smooth muscle and vasodilation. This results in decreased pulmonary artery pressure and resistance, improving exercise capacity and symptoms in patients with pulmonary arterial hypertension.
Approved indications
- Treatment of pulmonary arterial hypertension
Common side effects
- Headache
- Nausea
- Dizziness
- Flushing
- Pain in extremity
- Palpitations
- Cough
- Dyspnea
- Fatigue
- Diarrhea
Key clinical trials
- Field Study on Intravenous Iloprost for Treatment of Severe Frostbite at High Altitude
- Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)
- Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension
- Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years
- Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension
- Comparative PK PD Study in PAH Patients (Fox vs. I-Neb) (PHASE1, PHASE2)
- Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation
- Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ventavis (Iloprost, BAYQ6256) CI brief — competitive landscape report
- Ventavis (Iloprost, BAYQ6256) updates RSS · CI watch RSS
- Bayer portfolio CI